# A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

> **NCT07488676** · PHASE1,PHASE2 · RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** ASP546C

## Key facts

- **NCT ID:** NCT07488676
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-20
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07488676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07488676, "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07488676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*